RCG: Creació d'un Repositori per Impartir Competències Genèriques

[cat] Amb l’entrada dels nous plans d’estudis les competències genèriques han adquirit una importància que enfronta als professors a la necessitat de cercar activitats que ajudin al seu ensenyament. Per aquest motiu s’ha proposat crear, emprant l’esforç col·laboratiu, un repositori que reculli totes aquestes activitats i que les posi a disposició del professorat. D’aquesta manera ha sorgit el Repositori de Competències Genèriques, un espai col·laboratiu entre professors a on aquests poden crear activitats, cercar-les, classificar-les, comentar-les i votar-les, facilitant així la tasca de recollir i organitzar aquestes competències. La direcció del portal és http//reg.uib.e

CERVANTES: A Model-Based Approach for Service-Oriented Systems Development

Context: The benefits of the Model-Driven Software Engineering application for Service-Oriented Computing. Objective: This paper proposes a Model-Based approach for Service-Oriented Systems Development. Method: Following the Model-Driven Reverse Engineering process, from the models discovery, to the generation of the current Model-Based Approach for Service-Oriented Systems Development. Results: The CERVANTES metamodel is presented and compared to other initiatives. Conclusions: This study shows how Model-Driven Engineering can be used to develop Service Oriented Systems in practice

Delayed haemolysis after artesunate therapy in a cohort of patients with severe imported malaria due to Plasmodium falciparum

INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after treatment with intravenous artesunate in patients with severe malaria. Little is known about its frequency and the outcomes of patients with this condition. METHODS: A retrospective study was conducted to describe the incidence of delayed haemolysis in a cohort of patients with severe malaria by Plasmodium falciparum treated with artesunate between August 2013 and July 2015. RESULTS: The study included 52 patients with malaria due to Plasmodium falciparum, with 21 having severe malaria. The majority were male (66.7%), and the median age was 43 years. Four patients (19%) presented post-artesunate delayed haemolysis 11-13 days from the initiation of treatment. Two patients required hospital admission and red blood cell transfusion. CONCLUSION: Post-artesunate delayed haemolysis is frequent in patients with severe malaria treated with intravenous artemisinins. These patients should be monitored for 4 weeks after treatment is started

Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.

BACKGROUND: Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of vascular proliferation, could improve the vision of people with PDR. OBJECTIVES: To assess the effectiveness and safety of anti-VEGFs for PDR. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to April 2014), EMBASE (January 1980 to April 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 28 April 2014. SELECTION CRITERIA: We included randomised controlled trials (RCTs) comparing anti-VEGFs to another active treatment, sham treatment or no treatment for people with PDR. We also included studies that assessed the combination of anti-VEGFs with other treatments. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for inclusion, extracted data and assessed risk of bias for all included trials. We calculated the risk ratio (RR) or the mean difference (MD), and 95% confidence intervals (CI). MAIN RESULTS: We included 18 RCTs with 1005 participants (1131 eyes) of whom 57% were men. The median number of participants per RCT was 40 (range 15 to 261). The studies took place in Asia (three studies), Europe (two studies), the Middle East (seven studies), North America (three studies) and South America (three studies). Eight RCTs recruited people eligible for PRP, nine RCTs enrolled people with diabetes requiring vitrectomy and one RCT recruited people undergoing cataract surgery. The median follow-up was six months (range one to 12 months). Seven studies were at high risk of bias and the remainder were unclear risk of bias in one or more domains.Very low quality evidence from one study of 61 people showed that people treated with bevacizumab and PRP were less likely to lose 3 or more lines of visual acuity at 12 months compared with people treated with PRP alone (RR 0.19, 95% CI 0.05 to 0.81). People treated with anti-VEGF had an increased chance of gaining 3 or more lines of visual acuity but the effect was imprecise and compatible with no effect or being less likely to gain vision (RR 6.78, 95% CI 0.37 to 125.95). No other study reported these two outcomes. On average, people treated with anti-VEGF (bevacizumab, pegaptanib or ranibizumab) had better visual acuity at 12 months compared with people not receiving anti-VEGF (MD -0.07 logMAR, 95% CI -0.12 to -0.02; 5 RCTs, 373 participants, low quality evidence). There was some evidence to suggest a regression of PDR with smaller leakage on fluorescein angiography but it was difficult to estimate a pooled result from the two trials reporting this outcome. People receiving anti-VEGF were less likely to have vitreous or pre-retinal haemorrhage at 12 months (RR 0.32, 95% CI 0.16 to 0.65; 3 RCTs, 342 participants, low quality evidence). No study reported on fluorescein leakage or quality of life.All of the nine trials of anti-VEGF before or during vitrectomy investigated bevacizumab; most studies investigated bevacizumab before vitrectomy, one study investigated bevacizumab during surgery.People treated with bevacizumab and vitrectomy were less likely to lose 3 or more lines of visual acuity at 12 months compared with people given vitrectomy alone but the effect was imprecise and compatible with no effect or being more likely to lose vision (RR 0.49, 95% CI 0.08 to 3.14; 3 RCTs, 94 participants, low quality evidence). People treated with bevacizumab were more likely to gain 3 or more lines of visual acuity (RR 1.62, 95% CI 1.20 to 2.17; 3 RCTs, 94 participants, low quality evidence). On average, people treated with bevacizumab had better visual acuity at 12 months compared with people not receiving bevacizumab but there was uncertainty in the estimate (the CIs included 0; i.e. were compatible with no effect, and there was considerable inconsistency between studies; MD -0.24 logMAR, 95% CI -0.50 to 0.01; 6 RCTs, 335 participants, I(2) = 67%; low quality evidence). People receiving bevacizumab were less likely to have vitreous or pre-retinal haemorrhage at 12 months (RR 0.30, 95% CI 0.18 to 0.52; 7 RCTs, 393 participants, low quality evidence). No study reported on quality of life.Reasons for downgrading the quality of the evidence included risk of bias in included studies, imprecision of the estimates, inconsistency of effect estimates and indirectness (few studies reported at 12 months).Adverse effects were rarely reported and there was no evidence for any increased risk with anti-VEGF but given the relatively few studies that reported these, and the low event rate, the power of the analysis to detect any differences was low. AUTHORS' CONCLUSIONS: There was very low or low quality evidence from RCTs for the efficacy and safety of anti-VEGF agents when used to treat PDR over and above current standard treatments. However, the results suggest that anti-VEGFs can reduce the risk of intraocular bleeding in people with PDR. Further carefully designed clinical trials should be able to improve this evidence

PREVALENCE OF UNKNOWN DIABETES AND IMPAIRED GLUCOSE TOLERANCE IN PATIENTS WITH IMPAIRED FASTING GLUCOSE

There are many community-based studies on the prevalence of diabetes, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG). However, studies on the prevalence of IGT and diabetes unknown in patients with IFG, by 75-g oral glucose tolerance test (OGTT), are few and small.CIBEROBN is an Instituto de Salud Carlos III initiative. This work has been co-financied by CIBEROBN, Research Grants of the Ministerio de Economía y Competitividad of Spain (Instituto de Salud Carlos III: PI10/00913), and Consejería de Salud de la Junta de Andalucía of Spain (PI-0037/2008 and PI-0112-2013).Peer Reviewe

Las cuevas de la Sierra de Atapuerca y el uso humano del paisaje kárstico durante el Pleistoceno (Burgos, España)

El karst de la Sierra de Atapuerca representa un interesante sistema multinivel, inactivo y heredado de antiguos niveles de base plio-pleistocenos, que alberga los enclaves prehistóricos más importantes para el conocimiento del poblamiento antiguo en Eurasia, y que fue declarado Patrimonio de la Humanidad en 2000 por la UNESCO. Estas cuevas se originan a partir de conductos subhorizontales con paleodrenajes en sentido SN, localizándose la zona de descarga en la cabecera del río Pico. Los conductos están organizados en tres niveles principales que aparecen colgados entre 90 y 60 m sobre el actual cauce del río Arlanzón, coincidiendo con los niveles de base generados por sus terrazas fluviales T2, T3 y T5. La incisión fluvial liberó de las aguas los conductos superiores mientras se excavaban los niveles inferiores del karst. Las cuevas que iban quedando accesibles fueron utilizadas por la fauna y los homininos, conservando un registro arqueo-paleontológico de más de 1,2 Ma

Is it true coeliacs do not digest gliadin ?. Degradation pattern of gliadin in coeliac disease small intestinal mucosa

Prolyl-endopeptidase supplementation has been proposed to favour gliadin degradation as an alternative treatment for coeliac disease (CD), although the real usefulness of this therapy in vivo is still under discussion. 1 However, our data point to alternative treatments aiming to modify the intestinal microbiota in patients with CD by the use of probiotics and/or prebiotics. We propose that the induction of gliadin proteolysis in the human gut might not be the solution but the origin of CD

Assessing the influence of isotopic composition of water on that of clay minerals during chemical treatments.

The isotopic composition of hydrogen in authigenic minerals is a useful tool to reconstruct past paleo-environments. Clay minerals are an important component of authigenic minerals in soils and sediments but they usually occur with other compounds that must be eliminated before the analysis, such as organic matter and carbonates. Thus, various “pre-treatments” are used, generally involving dilute HCl and H2O2 solutions in water. In this work, the influence of the isotopic composition of the water used in these pre-treatment solutions is assessed, using ten different samples of clay minerals. The isotopic composition of hydrogen was measured in each sample after HCl pre-treatment alone, H2O2 pre-treatment alone and both HCl and H2O2 pre-treatments in sequence, using two types of water in the pre-treatment solutions: one 2H-enriched and one 2H-depleted. The results indicate some influence of the isotopic composition of the water on the clay minerals after pre-treatment. In general, the samples showed significant alteration by HCl pre-treatment and negligible alteration by H2O2 pre-treatment. A pure kaolinite reference material did not show any change by chemical pre-treatment while a smectite reference material did show significant effects. Other samples (Ethiopian lacustrine sediment samples and Spanish cave sediments) showed important differences, which also depend on clay mineralogy. Thus, mineralogy seems to be the main cause of the variability in the alteration, especially the quantity of smectite. In addition, this result challenges the utility of clay minerals for isotope studies in acid conditions, such as in acidic soils, to reconstruct past environments and, therefore, climate changes.This study was developed during a stay supported by predoctoral mobility grant from the Spanish MINECO. Financial support for this work was obtained from MINECO Grant CGL2015-65387-C3-3-P. I. Campaña was the beneficiary of a predoctoral FPI Grant from the Spanish MINECO. We thank Jessica Wilson at the University of South Florida School of Geosciences who supported the isotopic analysis. J.G. Wynn was supported by an NSF IR/D program. Special thanks to the local resident of Burgos that help us remove the car from a mud puddle. // Funding for open access charge: Universidad de Málaga / CBU

Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study

Producción CientíficaIn comparison with hip fractures, increased expression of genes in the Wnt pathway and increased Wnt activity were found in bone samples and osteoblast cultures from patients with osteoarthritis, suggesting the involvement of this pathway in subchondral bone changes. No consistent differences were found in the genetic association study